In line with previously published reports [53], a clear dose-dependent relationship was observed between therapeutic efficacy and anti-CTLA4 dosage, with administration of a cumulative 10 mg/kg resulting in remarkable tumor inhibition (Fig. 5 B – E, Fig. S4). This evidence concerns the gene CTLA4 and neoplasm.